Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 20
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Vivos Therapeutics Inc
VVOS
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$0.1297
-0.0052
-3.85%
Dern. MÀJ: Oct 20, 11:05 AM
$0.1348
-0.0001
-0.07%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Rapport sur les stocks
Privacy Manager
Fusions et acquisitions:
SOD Sciences, Inc. was acquired by Vivos Therapeutics (VVOS) on Monday, October 19, 2026 for $12M
Vivos Therapeutics Financials
Vivos Therapeutics (VVOS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Vivos Therapeutics Q2 EPS $(0.31) Beats $(0.36) Estimate, Sales $5.153M Miss $5.367M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.36) by 13.89 percent. This is a 43.64 percent increase over losses of $(0.55) per share
Benzinga Newsdesk
PRO
Vivos Therapeutics Q1 EPS $(0.52) Misses $(0.45) Estimate, Sales $5.141M Beat $4.225M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.45) by 15.56 percent. This is a 15.56 percent decrease over losses of $(0.45) per share
Benzinga Newsdesk
PRO
Vivos Therapeutics Q4 EPS $(0.58) Misses $(0.48) Estimate, Sales $3.824M Miss $6.447M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.48) by 20.83 percent. This is a 107.14 percent decrease over losses of $(0.28) per share
Benzinga Newsdesk
Broadcom, Vivos Therapeutics And 3 Stocks To Watch Heading Into Monday
U.S. stocks mixed, Cheer Holding announces reverse stock split, Vivos Therapeutics gains investor stake, Quhuo Ltd. reports loss.
Avi Kapoor
PRO
Vivos Therapeutics Q3 EPS $(0.49) Misses $(0.41) Estimate, Sales $6.783M Beat $4.686M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.41) by 18.07 percent. This is a 22.5 percent decrease over losses of $(0.40) per share
Benzinga Newsdesk
PRO
Vivos Therapeutics Q2 EPS $(0.55) Misses $(0.35) Estimate, Sales $3.820M Beat $3.783M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.35) by 57.14 percent. This is a 8.33 percent increase over losses of $(0.60) per share
Benzinga Newsdesk
